Therapeutic Advances in Endocrinology and Metabolism · Aug 26, 2026

GLP-1 receptor agonists at the crossroads of metabolic and gut inflammation: Implications for people with type 2 diabetes and inflammatory bowel disease

By Dardari D

Obesity and type 2 diabetes now coexist with IBD. Beyond glucose and weight effects, GLP-1 receptor agonists reduce MACE and lower systemic inflammatory biomarkers. Observational IBD data suggest acceptable safety and fewer hospitalisations and surgeries, warranting carefully designed prospective trials.

doi.org/10.1177/20420188261478400 Open access PubMed 42662155 Interventions